Baglan Askeyev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Baglan Askeyev has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Hajime Matsushima
Department of Surgery Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
5 shared publications - Akihiko Soyama
Department of Surgery Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
4 shared publications - Hajime Imamura
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan
4 shared publications - Susumu Eguchi
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
4 shared publications - Tomohiko Adachi
Department of Surgery Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
3 shared publications - A. S. Skakbayev
National Scientific Center of Surgery named after A.N. Syzganov, Almaty, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 22 (2) , 14-24
BILIARY COMPLICATIONS AFTER LIVER TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Background. Biliary complications remain a major cause of morbidity after liver transplantation, with a higher incidence reported in living donor liver transplantation compared with deceased donor liver transplantation. This study aimed to systematically evaluate the incidence, risk factors, and clinical outcomes of biliary complications following liver transplantation. Materials and Methods. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Data were retrieved from PubMed/MEDLINE, Scopus, and Web of Science up to 2025. Observational cohort and comparative studies reporting biliary complications after living donor liver transplantation and/or deceased donor liver transplantation were included. Results. Fifteen studies comprising 16,579 patients were included. The overall incidence of biliary complications ranged from 10% to 35%, reaching up to 40% in living donor liver transplantation recipients. Meta-analysis demonstrated a significantly higher risk of biliary complications in living donor liver transplantation compared with deceased donor liver transplantation (OR = 1.96). Anastomotic strictures were the most common complication, while non-anastomotic strictures were associated with poorer graft survival and increased retransplantation rates. Key risk factors included multiple biliary anastomoses, ischemia–reperfusion injury, hepatic artery thrombosis, and prolonged cold ischemia time. Conclusions. Biliary complications remain a frequent and clinically significant problem after liver transplantation, particularly in living donor liver transplantation. Their development is multifactorial, predominantly driven by ischemic and technical factors. These findings highlight the importance of optimizing surgical techniques and perioperative management to improve graft outcomes.
- 30 June 2026
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 22 (2) , 14-24
Open AccessBILIARY COMPLICATIONS AFTER LIVER TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Background. Biliary complications remain a major cause of morbidity after liver transplantation, with a higher incidence reported in living donor liver transplantation compared with deceased donor liver transplantation. This study aimed to systematically evaluate the incidence, risk factors, and clinical outcomes of biliary complications following liver transplantation. Materials and Methods. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Data were retrieved from PubMed/MEDLINE, Scopus, and Web of Science up to 2025. Observational cohort and comparative studies reporting biliary complications after living donor liver transplantation and/or deceased donor liver transplantation were included. Results. Fifteen studies comprising 16,579 patients were included. The overall incidence of biliary complications ranged from 10% to 35%, reaching up to 40% in living donor liver transplantation recipients. Meta-analysis demonstrated a significantly higher risk of biliary complications in living donor liver transplantation compared with deceased donor liver transplantation (OR = 1.96). Anastomotic strictures were the most common complication, while non-anastomotic strictures were associated with poorer graft survival and increased retransplantation rates. Key risk factors included multiple biliary anastomoses, ischemia–reperfusion injury, hepatic artery thrombosis, and prolonged cold ischemia time. Conclusions. Biliary complications remain a frequent and clinically significant problem after liver transplantation, particularly in living donor liver transplantation. Their development is multifactorial, predominantly driven by ischemic and technical factors. These findings highlight the importance of optimizing surgical techniques and perioperative management to improve graft outcomes.
- Open Access
- 18 May 2026
- Published by Springer Nature in BMC Research Notes
- Vol. 19 (1)
Feasibility of serial cfDNA measurement after perflubutane microbubble (Sonazoid®) administration in patients with pancreatic ductal adenocarcinoma: a first-in-human pilot study
Circulating cell-free DNA (cfDNA) is a promising liquid biopsy biomarker in pancreatic ductal adenocarcinoma (PDAC), but clinical sensitivity remains limited, particularly in localized disease. Experimental studies suggest that transient modulation of hepatic clearance may increase recoverable cfDNA. Perflubutane microbubbles (Sonazoid®), a clinically approved ultrasound contrast agent, are selectively taken up by Kupffer cells and may influence short-term cfDNA kinetics. This first-in-human pilot study primarily aimed to assess the feasibility and safety of serial cfDNA sampling and quantification following Sonazoid® administration in patients with resectable or borderline-resectable PDAC. This single-center prospective pilot study enrolled patients with resectable or borderline-resectable PDAC scheduled for curative-intent surgery. Perflubutane microbubbles (Sonazoid®) were administered intravenously at the standard diagnostic dose (0.015 mL/kg). Blood samples were collected at baseline and at 5, 15, 30, and 60 min after administration. Plasma cfDNA was extracted using a standardized protocol and quantified in duplicate by fluorometric analysis. The primary objective was feasibility, defined as successful completion of serial blood sampling, plasma processing, cfDNA extraction, and quantitative cfDNA measurement, as well as procedural safety. Changes in cfDNA concentration were assessed descriptively as an exploratory outcome. Five patients were enrolled, and all completed the full protocol without deviations. Of these, four had resectable disease and one had borderline-resectable disease. Clinical stage at presentation ranged from IB to IIIA. Serial blood collection, plasma processing, cfDNA extraction, and fluorometric quantification were successfully performed for all 25 planned samples. Baseline cfDNA concentrations ranged from 0.564 to 0.946 ng/µL. Four patients showed a decrease in cfDNA concentration at 5 min followed by relative stability through 60 min, whereas one patient demonstrated a transient greater-than-two-fold increase at 5 min, followed by persistently higher-than-baseline values through 60 min. At the cohort level, no consistent increase in cfDNA concentration was observed. No adverse events related to Sonazoid® administration were observed. Serial peri-procedural cfDNA measurement using standardized sampling and fluorometric quantification was feasible and safe in patients with resectable or borderline-resectable PDAC. Administration of perflubutane microbubbles at standard diagnostic doses did not induce a uniform or sustained increase in circulating cfDNA concentrations in this pilot cohort. These findings provide feasibility data and may inform the design of future studies evaluating cfDNA dynamics after clearance-modulating interventions in PDAC. Trial Registration This study is registered in the Japan Registry of Clinical Trials (jRCT) under the identifier jRCTs071240095, registered on January 10, 2025. Registration details are available at: https://jrct.mhlw.go.jp/latest-detail/jRCTs071240095.
- 18 May 2026
- Published by Springer Nature in BMC Research Notes
- Vol. 19 (1)
Open AccessFeasibility of serial cfDNA measurement after perflubutane microbubble (Sonazoid®) administration in patients with pancreatic ductal adenocarcinoma: a first-in-human pilot study
Circulating cell-free DNA (cfDNA) is a promising liquid biopsy biomarker in pancreatic ductal adenocarcinoma (PDAC), but clinical sensitivity remains limited, particularly in localized disease. Experimental studies suggest that transient modulation of hepatic clearance may increase recoverable cfDNA. Perflubutane microbubbles (Sonazoid®), a clinically approved ultrasound contrast agent, are selectively taken up by Kupffer cells and may influence short-term cfDNA kinetics. This first-in-human pilot study primarily aimed to assess the feasibility and safety of serial cfDNA sampling and quantification following Sonazoid® administration in patients with resectable or borderline-resectable PDAC. This single-center prospective pilot study enrolled patients with resectable or borderline-resectable PDAC scheduled for curative-intent surgery. Perflubutane microbubbles (Sonazoid®) were administered intravenously at the standard diagnostic dose (0.015 mL/kg). Blood samples were collected at baseline and at 5, 15, 30, and 60 min after administration. Plasma cfDNA was extracted using a standardized protocol and quantified in duplicate by fluorometric analysis. The primary objective was feasibility, defined as successful completion of serial blood sampling, plasma processing, cfDNA extraction, and quantitative cfDNA measurement, as well as procedural safety. Changes in cfDNA concentration were assessed descriptively as an exploratory outcome. Five patients were enrolled, and all completed the full protocol without deviations. Of these, four had resectable disease and one had borderline-resectable disease. Clinical stage at presentation ranged from IB to IIIA. Serial blood collection, plasma processing, cfDNA extraction, and fluorometric quantification were successfully performed for all 25 planned samples. Baseline cfDNA concentrations ranged from 0.564 to 0.946 ng/µL. Four patients showed a decrease in cfDNA concentration at 5 min followed by relative stability through 60 min, whereas one patient demonstrated a transient greater-than-two-fold increase at 5 min, followed by persistently higher-than-baseline values through 60 min. At the cohort level, no consistent increase in cfDNA concentration was observed. No adverse events related to Sonazoid® administration were observed. Serial peri-procedural cfDNA measurement using standardized sampling and fluorometric quantification was feasible and safe in patients with resectable or borderline-resectable PDAC. Administration of perflubutane microbubbles at standard diagnostic doses did not induce a uniform or sustained increase in circulating cfDNA concentrations in this pilot cohort. These findings provide feasibility data and may inform the design of future studies evaluating cfDNA dynamics after clearance-modulating interventions in PDAC. Trial Registration This study is registered in the Japan Registry of Clinical Trials (jRCT) under the identifier jRCTs071240095, registered on January 10, 2025. Registration details are available at: https://jrct.mhlw.go.jp/latest-detail/jRCTs071240095.
- Open Access
- 16 January 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Robotic pancreaticoduodenectomy in patients with hepatic arterial variants: surgical outcomes and technical considerations in a single-center cohort
Purpose Hepatic arterial anomalies are commonly encountered during pancreaticoduodenectomy. However, their impact on perioperative outcomes in robotic pancreaticoduodenectomy (RPD) remains unclear. Methods We retrospectively analyzed 79 consecutive patients who underwent RPD. Hepatic arterial anatomy was classified according to the systems of Michels and Hiatt. Perioperative outcomes were compared between patients with hepatic arterial variants and those with normal anatomy. Results Hepatic arterial anomalies were identified in 22 patients (27.8%). According to Hiatt’s classification, 57 patients (72.2%) had normal type I anatomy, while type II and III variants were observed in 4 (5.1%) and 9 (11.4%) patients, respectively. Two patients exhibited type IV variants with both replaced right and left hepatic arteries. Data are presented in the order of absence and presence of arterial anomalies. Median age was similar (72 vs. 73 years, P = 0.86), with no difference in sex distribution (P = 0.25). Operative time (549 vs. 586 min, P = 0.92), blood loss (73 vs. 50 mL, P = 0.49), rates of clinically relevant postoperative pancreatic fistula (5.3% vs. 4.5%, P = 0.69), postoperative bleeding(0% vs. 4.5%, P = 0.27), pseudoaneurysm hemorrhage (5.3% vs. 0%, P = 0.55), and major complications (Clavien–Dindo grade ≥ 3a) (8.8% vs. 9.0%, P = 0.63) did not differ significantly. Conclusion The presence of hepatic arterial anomalies did not adversely affect perioperative outcomes in patients undergoing RPD. These findings suggest that, with appropriate preoperative planning and meticulous surgical technique, RPD can be performed safely in selected patients with hepatic arterial variants at experienced centers.
- 16 January 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Open AccessRobotic pancreaticoduodenectomy in patients with hepatic arterial variants: surgical outcomes and technical considerations in a single-center cohort
Purpose Hepatic arterial anomalies are commonly encountered during pancreaticoduodenectomy. However, their impact on perioperative outcomes in robotic pancreaticoduodenectomy (RPD) remains unclear. Methods We retrospectively analyzed 79 consecutive patients who underwent RPD. Hepatic arterial anatomy was classified according to the systems of Michels and Hiatt. Perioperative outcomes were compared between patients with hepatic arterial variants and those with normal anatomy. Results Hepatic arterial anomalies were identified in 22 patients (27.8%). According to Hiatt’s classification, 57 patients (72.2%) had normal type I anatomy, while type II and III variants were observed in 4 (5.1%) and 9 (11.4%) patients, respectively. Two patients exhibited type IV variants with both replaced right and left hepatic arteries. Data are presented in the order of absence and presence of arterial anomalies. Median age was similar (72 vs. 73 years, P = 0.86), with no difference in sex distribution (P = 0.25). Operative time (549 vs. 586 min, P = 0.92), blood loss (73 vs. 50 mL, P = 0.49), rates of clinically relevant postoperative pancreatic fistula (5.3% vs. 4.5%, P = 0.69), postoperative bleeding(0% vs. 4.5%, P = 0.27), pseudoaneurysm hemorrhage (5.3% vs. 0%, P = 0.55), and major complications (Clavien–Dindo grade ≥ 3a) (8.8% vs. 9.0%, P = 0.63) did not differ significantly. Conclusion The presence of hepatic arterial anomalies did not adversely affect perioperative outcomes in patients undergoing RPD. These findings suggest that, with appropriate preoperative planning and meticulous surgical technique, RPD can be performed safely in selected patients with hepatic arterial variants at experienced centers.
- 1 July 2025
- Published by Wiley in Hepatology Research
- Vol. 55 (10) , 1398-1403
Investigation of Possible Telomerase Reverse Transcriptase Promoter Mutation in Human Chemically Induced Liver Progenitors
Aim: This study aimed to investigate the presence of telomerase reverse transcriptase (TERT) promoter mutations in human chemically induced liver progenitors (hCLiPs) and to evaluate their potential association with carcinogenesis.Methods: TERT promoter mutations were analyzed in 20 formalin‐fixed, paraffin‐embedded HCC samples, 19 liver cirrhosis (LC) samples, and five hCLiPs derived from cirrhotic liver tissue. Genomic DNA was extracted, and droplet digital PCR was performed to detect TERT promoter mutations (C228T and C250T).Results: No TERT promoter mutations were detected in hCLiPs or LC samples. In contrast, 11 of 20 (55%) HCC samples carried the C228T mutation, with mutant allele frequencies ranging from 2.7% to 28.0% (mean ± SD: 21.6 ± 11.05%). The C250T mutation was not identified in any sample.Conclusion: These findings show that hCLiPs reprogrammed using small molecules do not harbor TERT promoter mutations, supporting their genomic stability and potential safety for clinical applications.
- 1 July 2025
- Published by Wiley in Hepatology Research
- Vol. 55 (10) , 1398-1403
Investigation of Possible Telomerase Reverse Transcriptase Promoter Mutation in Human Chemically Induced Liver Progenitors
Aim: This study aimed to investigate the presence of telomerase reverse transcriptase (TERT) promoter mutations in human chemically induced liver progenitors (hCLiPs) and to evaluate their potential association with carcinogenesis.Methods: TERT promoter mutations were analyzed in 20 formalin‐fixed, paraffin‐embedded HCC samples, 19 liver cirrhosis (LC) samples, and five hCLiPs derived from cirrhotic liver tissue. Genomic DNA was extracted, and droplet digital PCR was performed to detect TERT promoter mutations (C228T and C250T).Results: No TERT promoter mutations were detected in hCLiPs or LC samples. In contrast, 11 of 20 (55%) HCC samples carried the C228T mutation, with mutant allele frequencies ranging from 2.7% to 28.0% (mean ± SD: 21.6 ± 11.05%). The C250T mutation was not identified in any sample.Conclusion: These findings show that hCLiPs reprogrammed using small molecules do not harbor TERT promoter mutations, supporting their genomic stability and potential safety for clinical applications.
- Open Access
- 8 October 2024
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e945859
Real-Time Depiction of Intrahepatic Biliary Anatomy During Recipient Surgery with Contrast-Enhanced Ultrasonography in Living-Donor Liver Transplantation
BACKGROUND In living-donor liver transplantation, biliary complications are considered an Achilles' heel. Consequently, various attempts have been made to reduce their incidence, and multiple innovations in surgical techniques have been reported. We herein report a case involving an intraoperative ultrasound cholangiogram in the recipient's abdominal cavity after reperfusion of the graft. CASE REPORT A 39-year-old male patient with decompensated alcoholic liver cirrhosis was admitted to our hospital for living-donor liver transplantation. The donor was his younger brother. Preoperative magnetic resonance cholangiopancreatography revealed no evidence of biliary anatomical variance; this could have been problematic when donating the left lobe graft. Intraoperative cholangiography showed that the left hepatic duct was sufficiently long for division, guaranteeing donor safety. Back-table observation of the bile duct revealed 3 orifices; of these, the central orifice was very small, and the corresponding bile duct was not evident on intraoperative cholangiography in donor surgery. After an injection of perfluorobutane microbubbles (Sonazoid) diluted 1000-fold into the small central orifice, the bile duct of segment 4 (B4) was clearly visualized with an intraoperative ultrasound cholangiogram. The off-label use of Sonazoid was approved by Nagasaki University Hospital. Based on this finding, we determined that all 3 openings required reconstruction and reconstructed them using a telescope reconstruction method. CONCLUSIONS We verified that intraoperative ultrasound cholangiogram is useful as a tool to confirm the anatomy of the bile duct when it is not revealed through other evaluation techniques; hence, it is a method that transplant surgeons should be familiar with.
- 8 October 2024
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e945859
Open AccessReal-Time Depiction of Intrahepatic Biliary Anatomy During Recipient Surgery with Contrast-Enhanced Ultrasonography in Living-Donor Liver Transplantation
BACKGROUND In living-donor liver transplantation, biliary complications are considered an Achilles' heel. Consequently, various attempts have been made to reduce their incidence, and multiple innovations in surgical techniques have been reported. We herein report a case involving an intraoperative ultrasound cholangiogram in the recipient's abdominal cavity after reperfusion of the graft. CASE REPORT A 39-year-old male patient with decompensated alcoholic liver cirrhosis was admitted to our hospital for living-donor liver transplantation. The donor was his younger brother. Preoperative magnetic resonance cholangiopancreatography revealed no evidence of biliary anatomical variance; this could have been problematic when donating the left lobe graft. Intraoperative cholangiography showed that the left hepatic duct was sufficiently long for division, guaranteeing donor safety. Back-table observation of the bile duct revealed 3 orifices; of these, the central orifice was very small, and the corresponding bile duct was not evident on intraoperative cholangiography in donor surgery. After an injection of perfluorobutane microbubbles (Sonazoid) diluted 1000-fold into the small central orifice, the bile duct of segment 4 (B4) was clearly visualized with an intraoperative ultrasound cholangiogram. The off-label use of Sonazoid was approved by Nagasaki University Hospital. Based on this finding, we determined that all 3 openings required reconstruction and reconstructed them using a telescope reconstruction method. CONCLUSIONS We verified that intraoperative ultrasound cholangiogram is useful as a tool to confirm the anatomy of the bile duct when it is not revealed through other evaluation techniques; hence, it is a method that transplant surgeons should be familiar with.
- Open Access
- 3 July 2024
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e944405-e944405-5
Repeated Minimally Invasive Pancreatectomy for Intraductal Papillary Mucinous Neoplasm in the Remnant Pancreas: A Case Report
Repeated Minimally Invasive Pancreatectomy for Intraductal Papillary Mucinous Neoplasm in the Remnant Pancreas: A Case Report - Article abstract #944405
- 3 July 2024
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e944405-e944405-5
Open AccessRepeated Minimally Invasive Pancreatectomy for Intraductal Papillary Mucinous Neoplasm in the Remnant Pancreas: A Case Report
Repeated Minimally Invasive Pancreatectomy for Intraductal Papillary Mucinous Neoplasm in the Remnant Pancreas: A Case Report - Article abstract #944405
- 1 June 2023
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- p. 5-14
OUR EXPERIENCE OF LAPAROSCOPIC PANCREATODUODENECTOMY IN TUMORS OF THE PERIAMPULLARY ZONE
The purpose of research is to determine the feasibility of laparoscopic pancreatoduodenectomy in tumors of the periampullary zone. Material and methods. In the period from 2016 to 2022 at the Syzganov National Scientific Center of Surgery, 193 patients underwent PD with a diagnosis of a tumor of the periampullary zone. Of these, 6 patients were performed laparoscopically. All patients who underwent LPD were female. The age of the patients ranged from 15 to 77 years (average age – 55,7 years). Results. In 4 (66.7%) patients, cancer of Ampulla of Vater was detected, in 2 (33.3%) pancreatic head cancer. According to the final histology data, adenocarcinoma and the degree of differentiation G2 were detected in all cases. Data on the histology and size of the tumor are summarized in Table 1. The average age of patients was 55.7 years. All patients had a clinic of mechanical jaundice before surgery; the average levels of bilirubin in the blood were 121.3 mmol/l. Accordingly, all patients underwent drainage of the biliary tract. Of these, 5 (83.3%) patients underwent percutaneous stenting and 1 (16.7%) endobiliary stenting. Conclusion. Thus, we presented our initial experience of performing laparoscopic PD. Our results shows the feasibility of laparoscopic PD safely and radically for tumors of the periampullary zone in certain cases. The accumulation of experience in such interventions leads to an improvement in immediate results and a reduction in postoperative complications, the operative time.
- 1 June 2023
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- p. 5-14
OUR EXPERIENCE OF LAPAROSCOPIC PANCREATODUODENECTOMY IN TUMORS OF THE PERIAMPULLARY ZONE
The purpose of research is to determine the feasibility of laparoscopic pancreatoduodenectomy in tumors of the periampullary zone. Material and methods. In the period from 2016 to 2022 at the Syzganov National Scientific Center of Surgery, 193 patients underwent PD with a diagnosis of a tumor of the periampullary zone. Of these, 6 patients were performed laparoscopically. All patients who underwent LPD were female. The age of the patients ranged from 15 to 77 years (average age – 55,7 years). Results. In 4 (66.7%) patients, cancer of Ampulla of Vater was detected, in 2 (33.3%) pancreatic head cancer. According to the final histology data, adenocarcinoma and the degree of differentiation G2 were detected in all cases. Data on the histology and size of the tumor are summarized in Table 1. The average age of patients was 55.7 years. All patients had a clinic of mechanical jaundice before surgery; the average levels of bilirubin in the blood were 121.3 mmol/l. Accordingly, all patients underwent drainage of the biliary tract. Of these, 5 (83.3%) patients underwent percutaneous stenting and 1 (16.7%) endobiliary stenting. Conclusion. Thus, we presented our initial experience of performing laparoscopic PD. Our results shows the feasibility of laparoscopic PD safely and radically for tumors of the periampullary zone in certain cases. The accumulation of experience in such interventions leads to an improvement in immediate results and a reduction in postoperative complications, the operative time.
- 30 December 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 4,p. 5-12
EFFICACY OF PERCUTANEOUS TRANSHEPATIC CHOLECYSTOSTOMY IN ACUTEOBSTRUCTIVE CHOLECYSTITIS
Acute obstructive cholecystitis is a common disease with a significant risk of mortality and complications. Active surgical tactics, such as open and laparoscopic access, pose a significant risk for elderly patients with concomitant diseases on the background of acute cholecystitis. The aim of our study is to analyze the effectiveness of percutaneous transhepatic cholecystostomy (PTCS) in acute obstructive cholecystitis (AOC) and subsequent laparoscopic cholecystectomy (LCE). Materials and methods. Retrospectively, we analyzed 64 patients treated with AOC in the period from 2017 to 2021 at the NSCS named after A.N. Syzganov. We divided them into 2 groups depending on surgical treatment. The first group: patients who were performedPTCS (n=29) at the first stage. The second stage, LCE was performed during the waiting period from 3 days to 72 days. The second group: patients who underwent LCE without drainage of the gallbladder (n=35). Also, the patients of the first group were divided into 3 subgroups depending on the waiting time: group A - LCE was performed within 10 days after PTCS, subgroup B - LCE was performed after from 2 to 4 weeks (n=12), patients of the subgroup C, LCE were performed after 4 weeks after PTCS. Preoperative, intraoperative data and postoperative complications were analyzed. Results. According to preoperative data, there was no significant difference in body temperature, laboratory data and concomitant diseases. The statistical difference was revealed only in the age of patients (65.3±9.0 vs 53.4±15.4). The duration of the operation in the second group of LCE was longer compared to the first group, but no significant difference was detected (108.1 ± 30.5 vs 117.9 ± 39.9). In the postoperative period after LCE, complications were observed in 5 (14.2%) cases: bleeding in 4 (11.4%) cases and suppuration of the postoperative wound in 1 (2.8%) case. Conversion was performed in 10 (15.6%) cases, and in one (1.5%) case, the choledochal wall was injured intraoperatively. There was no significant difference between groups A, B and C. Conclusion.The use of two-stage treatment significantly reduces the conversion to open surgery, significantly reduces postoperative complications and hospital stay in the postoperative period. According to the results of our research, the most optimal interval between PTCS and LCE is a period of more than 4 weeks.
- 30 December 2022
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- No. 4,p. 5-12
EFFICACY OF PERCUTANEOUS TRANSHEPATIC CHOLECYSTOSTOMY IN ACUTEOBSTRUCTIVE CHOLECYSTITIS
Acute obstructive cholecystitis is a common disease with a significant risk of mortality and complications. Active surgical tactics, such as open and laparoscopic access, pose a significant risk for elderly patients with concomitant diseases on the background of acute cholecystitis. The aim of our study is to analyze the effectiveness of percutaneous transhepatic cholecystostomy (PTCS) in acute obstructive cholecystitis (AOC) and subsequent laparoscopic cholecystectomy (LCE). Materials and methods. Retrospectively, we analyzed 64 patients treated with AOC in the period from 2017 to 2021 at the NSCS named after A.N. Syzganov. We divided them into 2 groups depending on surgical treatment. The first group: patients who were performedPTCS (n=29) at the first stage. The second stage, LCE was performed during the waiting period from 3 days to 72 days. The second group: patients who underwent LCE without drainage of the gallbladder (n=35). Also, the patients of the first group were divided into 3 subgroups depending on the waiting time: group A - LCE was performed within 10 days after PTCS, subgroup B - LCE was performed after from 2 to 4 weeks (n=12), patients of the subgroup C, LCE were performed after 4 weeks after PTCS. Preoperative, intraoperative data and postoperative complications were analyzed. Results. According to preoperative data, there was no significant difference in body temperature, laboratory data and concomitant diseases. The statistical difference was revealed only in the age of patients (65.3±9.0 vs 53.4±15.4). The duration of the operation in the second group of LCE was longer compared to the first group, but no significant difference was detected (108.1 ± 30.5 vs 117.9 ± 39.9). In the postoperative period after LCE, complications were observed in 5 (14.2%) cases: bleeding in 4 (11.4%) cases and suppuration of the postoperative wound in 1 (2.8%) case. Conversion was performed in 10 (15.6%) cases, and in one (1.5%) case, the choledochal wall was injured intraoperatively. There was no significant difference between groups A, B and C. Conclusion.The use of two-stage treatment significantly reduces the conversion to open surgery, significantly reduces postoperative complications and hospital stay in the postoperative period. According to the results of our research, the most optimal interval between PTCS and LCE is a period of more than 4 weeks.
- Open Access
- 20 January 2021
- Published by Healthcare of Kazakhstan in International Professional Journal "Medicine"
- Vol. 9-10 (219-220) , 2-10
Study of public opinion on post-mortem donation in the Republic of Kazakhstan
Goal. Find out the opinion of the Kazakh population about post-mortem organ donation to save the lives of patients with terminal diseases of organs in need of transplantation. Material and methods. The survey was conducted in the form of an anonymous online questionnaire. Our study involved 1176 people, of these, 309 are male and 867 are female. The survey participants were citizens of different regions of the country and different nationalities, the average age of the participants was 38.7±1 years (18-73 years). Results and discussion. 422 participants (36%) agreed to become a posthumous donor, and 644 (55%) refused to donate. 88 (7.6%) of the participants doubted their choice, the other 22 participants did not answer this question. During the survey, out of 1,176 respondents, 991 (84%) participants know that organ transplantation is being carried out in the country, of which 384 (38.7%) participants agree to post-mortem donation, and 607 (61.2%) participants refuse post-mortem donation. 185 (16%) participants are not informed that organ transplantation is being performed in the country, of which 49 (26.5%) participants agree to post-mortem donation, and 136 (73.5%) participants refuse post-mortem donation. As a result, it was found that informed participants agreed to post-mortem donation in 38.7% of cases, and uninformed participants agreed in only 26.5% of cases. Conclusion. For the development of organ transplantation from a cadaveric donor in Kazakhstan, it is necessary to inform the population about organ transplants carried out in large transplant centers of the country, and with good long-term results, to inform the population about the laws of the Republic of Kazakhstan on organ transplantation. It is very important for the population to guarantee security and huge support from the government of the country. In addition, for the development of organ transplantation from a posthumous donor in Kazakhstan, a lot depends not only on the population of the country itself, but also on social, moral, ethical, economic, and humanitarian support from the state government. Organ transplantation from a post-mortem donor is one of the most complex types of medical care, requiring a high level of professional and material support and coordinated actions at all levels of management. This area cannot develop without the support of society, the government, as well as without a positive view of the population. Keywords: organ transplantation, donor, opinion of the population of Kazakhstan.
- 20 January 2021
- Published by Healthcare of Kazakhstan in International Professional Journal "Medicine"
- Vol. 9-10 (219-220) , 2-10
Open AccessStudy of public opinion on post-mortem donation in the Republic of Kazakhstan
Goal. Find out the opinion of the Kazakh population about post-mortem organ donation to save the lives of patients with terminal diseases of organs in need of transplantation. Material and methods. The survey was conducted in the form of an anonymous online questionnaire. Our study involved 1176 people, of these, 309 are male and 867 are female. The survey participants were citizens of different regions of the country and different nationalities, the average age of the participants was 38.7±1 years (18-73 years). Results and discussion. 422 participants (36%) agreed to become a posthumous donor, and 644 (55%) refused to donate. 88 (7.6%) of the participants doubted their choice, the other 22 participants did not answer this question. During the survey, out of 1,176 respondents, 991 (84%) participants know that organ transplantation is being carried out in the country, of which 384 (38.7%) participants agree to post-mortem donation, and 607 (61.2%) participants refuse post-mortem donation. 185 (16%) participants are not informed that organ transplantation is being performed in the country, of which 49 (26.5%) participants agree to post-mortem donation, and 136 (73.5%) participants refuse post-mortem donation. As a result, it was found that informed participants agreed to post-mortem donation in 38.7% of cases, and uninformed participants agreed in only 26.5% of cases. Conclusion. For the development of organ transplantation from a cadaveric donor in Kazakhstan, it is necessary to inform the population about organ transplants carried out in large transplant centers of the country, and with good long-term results, to inform the population about the laws of the Republic of Kazakhstan on organ transplantation. It is very important for the population to guarantee security and huge support from the government of the country. In addition, for the development of organ transplantation from a posthumous donor in Kazakhstan, a lot depends not only on the population of the country itself, but also on social, moral, ethical, economic, and humanitarian support from the state government. Organ transplantation from a post-mortem donor is one of the most complex types of medical care, requiring a high level of professional and material support and coordinated actions at all levels of management. This area cannot develop without the support of society, the government, as well as without a positive view of the population. Keywords: organ transplantation, donor, opinion of the population of Kazakhstan.